Page 5,273«..1020..5,2725,2735,2745,275..5,2805,290..»

Can High-Dose Statins Improve Outcomes after Aneurysm-Related Stroke?

Posted: Published on May 22nd, 2013

Planned Trial Will Evaluate Simvastatin Treatment for Aneurysmal Subarachnoid Hemorrhage, Reports Neurosurgery Newswise Philadelphia, Pa. (May 21, 2013) Can treatment with high doses of a cholesterol-lowering statin drug improve outcomes for patients with stroke caused by rupture and bleeding of brain aneurysms? An ongoing clinical trial will soon find out, according to an article in the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health. Together with other research already underway, the trial will help to determine whether statin medications are effective in limiting damage to the brain in patients with aneurysmal subarachnoid hemorrhage (SAH). The lead investigator is Dr. George Kwok Chu Wong of Chinese University of Hong Kong. Statins Show Promise in Treatment of Aneurysmal SAH Dr. Wong and colleagues outline their plans for a study to evaluate the benefits of high-dose simvastatin for patients with SAH caused by a ruptured aneurysm. Subarachnoid hemorrhage is a life-threatening type of stroke in which there is bleeding into the brain. It most commonly occurs when an aneurysma weak spot in one of the blood vessels supplying the brainruptures or breaks. Experimental studies, … Continue reading →

Comments Off on Can High-Dose Statins Improve Outcomes after Aneurysm-Related Stroke?

CORRECTING and REPLACING InVivo Therapeutics Announces Webcast for Annual Shareholders Meeting to Be Held on May 23rd

Posted: Published on May 22nd, 2013

CORRECTIONby InVivo Therapeutics CAMBRIDGE, Mass.--(BUSINESS WIRE)--Please replace the release dated May 17, 2013 with the following corrected version due to multiple revisions. The corrected release reads: INVIVO THERAPEUTICS ANNOUNCES WEBCAST FOR ANNUAL SHAREHOLDERS MEETING TO BE HELD ON MAY 23RD InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company will be conducting a webcast of the Annual Shareholders Meeting scheduled for Thursday, May 23, 2013 at 10:00 a.m. Eastern Daylight Time at the offices of Greenberg Traurig, LLP at One International Place, Boston, MA 02110. The webcast can be accessed by interested shareholders and other parties at https://eval.webex.com/eval/onstage/g.php?t=a&d=921101635. Attendees will be able to view the presentation and hear the webcast in listen-only mode. Please use shareholder when prompted for the event password. The meeting can also be accessible by telephone in listen-only mode. From the US, please dial 1-866-469-3239; from outside the US, please visit https://eval.webex.com/eval/globalcallin.php?serviceType=EC&ED=226655812&tollFree=1 to find the telephone line nearest to your country. All participants should reference Access Code 921 101 635. Slides from the meeting will be available to those viewing the webcast,and a replay of the webcast including … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on CORRECTING and REPLACING InVivo Therapeutics Announces Webcast for Annual Shareholders Meeting to Be Held on May 23rd

Queen's University scientist wins top national award for spinal cord research

Posted: Published on May 22nd, 2013

TORONTO, May 21, 2013 /CNW/ - A scientist from Queen's University has received the 2012 Barbara Turnbull Award for Spinal Cord Research, an annual prize supported through a partnership between the Barbara Turnbull Foundation for Spinal Cord Research, Brain Canada, and the CIHR Institute of Neurosciences, Mental Health and Addiction. Dr. Stephen Scott, a Professor in the Department of Biomedical and Molecular Sciences at Queen's University, received this honour in recognition of his outstanding research focused on helping Canadians who suffer the effects of spinal cord trauma and stroke. "Our Government is committed to advancing research that helps improve the health and quality of life of Canadians living with spinal cord injury," says the Honourable Steven Fletcher, Minister of State (Transport). "I offer my sincere congratulations to Dr. Scott and encourage him in his efforts to translate research findings into better treatment and health outcomes." "I am honoured and pleased to receive this prestigious award," says Dr. Scott. "It will help me provide a better understanding of how we control our movements so that we can ultimately improve mobility for people who have spinal cord injuries." Dr. Scott and his research team focus on how feedback to the primary motor … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Queen's University scientist wins top national award for spinal cord research

Interview with InVivo Therapeutics’ CEO to be Aired on Boston’s NPR Station WBUR This Morning

Posted: Published on May 22nd, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that an interview with InVivo Chief Executive Officer Frank Reynolds is scheduled to be aired on WBUR in Boston this morning during Morning Edition with Renee Montagne, Steve Inskeep and Bob Oakes. Morning Edition airs weekdays from 5:00 9:00am EDT, and the story will be aired at approximately 5:50am and 7:50am EDT. A recording will also be available to listeners on http://www.wbur.org. InVivo Therapeutics has pioneered a treatment that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery and prognosis after traumatic SCI. The U.S. Food and Drug Administration (FDA) recently granted two approvals to the Company. The first is for Humanitarian Use Device (HUD) designation of InVivos lead product, which the Company believes will expedite the products path to market, and the second gave the Company permission to begin a first-in-man clinical trial of the technology. WBUR is Bostons NPR news station and airs on radio station 90.9. About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is utilizing … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Interview with InVivo Therapeutics’ CEO to be Aired on Boston’s NPR Station WBUR This Morning

19th Parkinson's Unity Walk Raises More than $1.6 Million in Support of Parkinson's Research

Posted: Published on May 22nd, 2013

KINGSTON, N.J., May 21, 2013 /PRNewswire-USNewswire/ -- The Parkinson Alliance proudly announced today that the 19th Parkinson's Unity Walk held on Saturday, April 27, 2013 in New York City's Central Park, has thus far raised more than $1.6 million and united more than 10,000 walkers in raising awareness for Parkinson's disease and to support research for better treatments, and hopefully one day a cure. Contributions will continue to be accepted through May 28, 2013. The Parkinson's Unity Walk is the largest awareness and fundraising event for Parkinson's disease research in the United States. For participants, the Parkinson's Unity Walk represented much more than a one-day event. "The Parkinson's Unity Walk is more than a just a walk. It provides an opportunity for thousands of participants to all come together in support of the community. This day is about sharing stories and experiences, learning more about Parkinson's disease and its management and spending time at the booths of leading Parkinson's organizations and companies working on better treatments for people living with or impacted by this disease," said Carol Walton, Chief Executive Officer of The Parkinson Alliance. The Walk kicked off with an inspirational poem from May May Ali, social activist, daughter … Continue reading →

Posted in Parkinson's Treatment | Comments Off on 19th Parkinson's Unity Walk Raises More than $1.6 Million in Support of Parkinson's Research

Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study

Posted: Published on May 22nd, 2013

SAN DIEGO, May 21, 2013 /PRNewswire/ -- Ceregene, Inc. today announced additional efficacy data from a secondary analysis of its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin). CERE-120 is a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease. This exploratory analysis identified a more robust response to CERE-120 in Parkinson's patients diagnosed within 5 years prior to treatment relative to those diagnosed 10 years or more (p Raymond T. Bartus, Ph.D., executive vice president and chief scientific officer of Ceregene stated: "The concept that earlier-stage patients may respond better to neurotrophic factor therapies such as CERE-120 is consistent with the field's long-standing appreciation for their mechanism of action, as well as more recent information derived from autopsy brain tissue donated by Parkinson's disease patients. While a number of practical considerations will have to be addressed in order to design and execute clinical trials that enroll only early-stage patients, this additional exploratory analysis adds further empirical support that the concept deserves serious consideration." These and other efficacy and safety data related to the CERE-120 program were presented, by invitation, at a symposium at the American Society for Gene and Cell Therapy annual meeting … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study

Writer with MS uses her voice to write memoir

Posted: Published on May 22nd, 2013

By Amy Saunders The Columbus Dispatch Tuesday May 21, 2013 6:00 AM Lauri L. Wolf of Upper Arlington gathers her thoughts on a computer that responds to voice commands. To move the cursor across her computer screen, Lauri L. Wolf leans back on the headrest of her motorized wheelchair and turns her head left or right. Wake up, she says through a headset, launching the voice-recognition program to start speaking what she can no longer type. As many as eight hours a day for the past two years, Wolf dictated her thoughts until they filled the 151 pages titled The BS of My MS a memoir she wrote without the use of her hands. The 52-year-old Upper Arlington resident suffers a severe form of multiple sclerosis that has left her a quadriplegic, a prisoner in her own body. Throughout her 18 years with the disease, she hasnt found any books that address topics more personal than scientific especially about her primary-progressive MS, which affects 15 percent of MS patients. She decided to write one herself. As a pharmacist, who maintains her license by taking continuing-education courses, Wolf felt a sense of obligation to share her knowledge of the neurological disease. … Continue reading →

Posted in MS Treatment | Comments Off on Writer with MS uses her voice to write memoir

Biogen Idec seeking approval from the FDA for an injectable multiple sclerosis drug

Posted: Published on May 22nd, 2013

By Robert Weisman, Globe Staff Biogen Idec Inc., which cemented its place as the dominant multiple sclerosis drug maker in March when it won US approval to sell an MS pill, said Tuesday it has applied to the Food and Drug Administration to market a third injectable MS drug. The drug, called Plegridy, is a new version of the Weston biotechnology companys first -- and hugely successful -- MS treatment, Avonex. While both drugs have the same active ingredient, interferon beta, Biogen Idec has attached a polymer called polyethylene glycol, or peg, to Plegridy that increases the exposure of the drug, allowing patients to take doses less frequently. And unlike Avonex and other MS drugs received through intramuscular injections, Plegridy would be administered subcutaneously, or under the skin, which is less painful. We see this as part of our commitment to MS patients, said Douglas E. Williams, Biogen Idecs executive vice president of research and development. Its a convenient version of a drug thats been on the market for many years and has a track record of safety and efficacy. Williams said Plegridy met its goals of reducing the diseases effects -- including relapses and worsening disabilities -- in a … Continue reading →

Posted in MS Treatment | Comments Off on Biogen Idec seeking approval from the FDA for an injectable multiple sclerosis drug

Human Embryonic Stem Cells Cloned – Video

Posted: Published on May 22nd, 2013

Human Embryonic Stem Cells Cloned Human embryonic stem cells are cloned. Dolly, the cloned sheep was born on July 5th, 1996. 17 years later, human skin cells and an unfertilized donor egg wit... By: GeoBeatsNews … Continue reading →

Posted in Stem Cell Research | Comments Off on Human Embryonic Stem Cells Cloned – Video

PJTV: Cloning Is Shameful: Why Abortion Advocates Love Human Cloning – Video

Posted: Published on May 22nd, 2013

PJTV: Cloning Is Shameful: Why Abortion Advocates Love Human Cloning AlfonZo Rachel thinks clones and the science of cloning is a lot like medical marijuana. Hear why as Zo brings you the facts about this scary new science, an... By: PJTV … Continue reading →

Posted in Stem Cell Research | Comments Off on PJTV: Cloning Is Shameful: Why Abortion Advocates Love Human Cloning – Video

Page 5,273«..1020..5,2725,2735,2745,275..5,2805,290..»